AR075873A1 - Reconstitucion in situ de una vacuna para la administracion a un grupo de animales predeterminado - Google Patents
Reconstitucion in situ de una vacuna para la administracion a un grupo de animales predeterminadoInfo
- Publication number
- AR075873A1 AR075873A1 ARP100100856A ARP100100856A AR075873A1 AR 075873 A1 AR075873 A1 AR 075873A1 AR P100100856 A ARP100100856 A AR P100100856A AR P100100856 A ARP100100856 A AR P100100856A AR 075873 A1 AR075873 A1 AR 075873A1
- Authority
- AR
- Argentina
- Prior art keywords
- vaccine
- animals
- situ
- administration
- reconstitution
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Surgical Instruments (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicinal Preparation (AREA)
Abstract
Método para reconstituir una vacuna para la administracion a un grupo de animales predeterminado que comprende proveer un conjunto de multiples antígenos inactivados, estando presente cada antígeno inactivado en una forma liofilizada y envasado en un recipiente, proveer un vehículo líquido que es farmacéuticamente aceptable para los animales, determinar los riesgos para la salud con relacion a infecciones microbianas para este grupo de animales, establecer cuales de los uno o más antígenos inactivados en dicho conjunto corresponde a estos riesgos para la salud, tomar uno o más de los recipientes correspondientes a los uno o más antígenos inactivados y mezclar el contenido liofilizado de dichos uno o más recipientes con el vehículo para preparar la vacuna. Método para producir multiples antígenos inactivados distintos para reconstituir la vacuna, a un kit de partes y a un método para permitir la reconstitucion in situ de la vacuna. Reivindicacion 5: Un método de acuerdo con cualquiera de las reivindicaciones precedentes, caracterizado porque la forma liofilizada comprende una o más liosferas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16162609P | 2009-03-19 | 2009-03-19 | |
EP09155612 | 2009-03-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR075873A1 true AR075873A1 (es) | 2011-05-04 |
Family
ID=40875190
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100100856A AR075873A1 (es) | 2009-03-19 | 2010-03-18 | Reconstitucion in situ de una vacuna para la administracion a un grupo de animales predeterminado |
Country Status (9)
Country | Link |
---|---|
US (1) | US20120328667A1 (es) |
EP (1) | EP2408430A1 (es) |
JP (1) | JP2012520849A (es) |
CN (1) | CN102341097A (es) |
AR (1) | AR075873A1 (es) |
BR (1) | BRPI1009408A2 (es) |
TW (1) | TW201043267A (es) |
UY (1) | UY32498A (es) |
WO (1) | WO2010106095A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3673916A1 (en) * | 2013-12-03 | 2020-07-01 | Intervet International B.V. | Vaccine against lawsonia intracellularis and porcine circovirus2 |
PL3697804T3 (pl) | 2017-10-17 | 2024-01-03 | Intervet International B.V. | Rekombinowana ekspresja białka orf2 pcv2b w komórkach owadzich |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5452794A (en) * | 1977-09-30 | 1979-04-25 | Kousaku Yoshida | Extracting of polysacchride from capusle containing epidermis staphylococus |
JPS5459316A (en) * | 1977-10-18 | 1979-05-12 | Takeda Chem Ind Ltd | Preparation of stable, freeze-dried vaccine for japanese encephalitis |
JPS6013718A (ja) * | 1983-07-05 | 1985-01-24 | Chemo Sero Therapeut Res Inst | B型肝炎ワクチン |
JPS60193925A (ja) * | 1984-03-13 | 1985-10-02 | Chemo Sero Therapeut Res Inst | 凍結乾燥製剤化ワクチン |
JPH0761955B2 (ja) * | 1988-04-28 | 1995-07-05 | 国立予防衛生研究所長 | 凍結乾燥a型肝炎ワクチン |
KR100425929B1 (ko) * | 1995-06-23 | 2004-05-31 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 알루미늄포스페이트상에흡착된다당류컨쥬게이트항원을포함하는백신조성물 |
IL120202A (en) * | 1996-03-07 | 2001-03-19 | Akzo Nobel Nv | Container with freeze-dried vaccine components |
JPH09248177A (ja) | 1996-03-18 | 1997-09-22 | Snow Brand Milk Prod Co Ltd | 乾燥微生物菌体の製造法 |
EP0928209A1 (en) | 1996-09-26 | 1999-07-14 | Akzo Nobel N.V. | Needle-less injector |
CN1305374A (zh) * | 1998-07-14 | 2001-07-25 | 法玛西雅厄普约翰美国公司 | 治疗眼部感染的噁唑烷酮 |
WO2000037101A1 (en) * | 1998-12-21 | 2000-06-29 | Akzo Nobel N.V. | Method to produce inactivated w/o emulsion adjuvated vaccines |
EP1515763B1 (en) | 2002-06-10 | 2011-08-17 | Intervet International BV | Needle-less injector |
US7836606B2 (en) * | 2004-07-23 | 2010-11-23 | Bayer Technology Services Gmbh | Sterile freezing, drying, storing, assaying and filling process |
TW200626177A (en) * | 2004-09-28 | 2006-08-01 | Alza Corp | Method and formulation for stabilizing alum-adsorbed vaccines |
TWI398272B (zh) * | 2005-03-08 | 2013-06-11 | Intervet Int Bv | 化學定義的安定劑 |
CN101095950B (zh) * | 2006-06-30 | 2011-01-26 | 辽宁成大生物股份有限公司 | 一种稳定的人用狂犬病疫苗冻干制剂及其制备 |
-
2010
- 2010-03-01 TW TW099105818A patent/TW201043267A/zh unknown
- 2010-03-17 BR BRPI1009408A patent/BRPI1009408A2/pt not_active IP Right Cessation
- 2010-03-17 US US13/256,045 patent/US20120328667A1/en not_active Abandoned
- 2010-03-17 JP JP2012500235A patent/JP2012520849A/ja active Pending
- 2010-03-17 EP EP10708786A patent/EP2408430A1/en not_active Ceased
- 2010-03-17 WO PCT/EP2010/053446 patent/WO2010106095A1/en active Application Filing
- 2010-03-17 UY UY0001032498A patent/UY32498A/es unknown
- 2010-03-17 CN CN2010800105588A patent/CN102341097A/zh active Pending
- 2010-03-18 AR ARP100100856A patent/AR075873A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
BRPI1009408A2 (pt) | 2016-03-01 |
WO2010106095A1 (en) | 2010-09-23 |
CN102341097A (zh) | 2012-02-01 |
JP2012520849A (ja) | 2012-09-10 |
US20120328667A1 (en) | 2012-12-27 |
EP2408430A1 (en) | 2012-01-25 |
UY32498A (es) | 2010-10-29 |
TW201043267A (en) | 2010-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR124676A2 (es) | Formulación farmacéutica que comprende una droga biofarmacéutica | |
ITUA20163461A1 (it) | Una capsula, un sistema per preparare una bevanda potabile da tale capsula e uso di tale capsula in un dispositivo per la preparazione di una bevanda | |
DOP2009000222A (es) | Formulaciones estables de anticuerpo | |
AR091961A1 (es) | Inmunoconjugados y anticuerpos anti-etbr (receptor de endotelina b) | |
ECSP13013060A (es) | Composiciones de nucleasa terapéuticas y métodos | |
MX2017005575A (es) | Formulacion farmaceutica de anticuerpos anti-tnf alfa. | |
WO2013051878A3 (en) | Antibody specifically binding to epitope in sema domain of c-met | |
WO2013184976A3 (en) | Compositions and methods for antigen-specific tolerance | |
BR112018008017A2 (pt) | composição farmacêutica, método de preparação de composição farmacêutica líquida, kit farmacêutico, sistema de fornecimento de injeção | |
AR086823A1 (es) | Formulaciones de anticuerpo anti-c-met, metodos | |
AR101455A1 (es) | Molécula portadora | |
AR098996A1 (es) | Formulación compuesta para la administración por vía oral que comprende ezetimiba y rosuvastatina | |
BR112016026811A2 (pt) | formulação de anticorpo | |
BR112016013509A2 (pt) | “sistema para a administração de inoculantes microbianos e materiais e métodos relacionados”. | |
BR112013009164A2 (pt) | capsídeo de norovírus e proteína vp6 de rotavírus para uso como vacina combinada. | |
BR112015023523B8 (pt) | Composições farmacêuticas e recipiente de forma de dosagem única | |
WO2015054694A3 (en) | Therapeutic compositions and methods for addressing physiological stresses and aging | |
BR112015025748A2 (pt) | construção de dna para imunomodulação, composição farmacêutica, vacina, e uso de uma construção de dna | |
BR112017000515A2 (pt) | formulação de vacina contra rotavírus termoestável seca por liofilização e processo para preparação da mesma | |
CL2015001772A1 (es) | Composición farmacéutica para el tratamiento de dolor cabeza, y método de preparación de la misma. | |
BR112013029417A2 (pt) | composições de vacina de matriz proteica incluindo policátions | |
UY34567A (es) | Método y sistema para transcodificar contenido en modo remoto | |
AR075873A1 (es) | Reconstitucion in situ de una vacuna para la administracion a un grupo de animales predeterminado | |
BR112018014123A2 (pt) | formulação farmacêutica aquosa estável. | |
BR112016026239A8 (pt) | bebida láctea, processo para a preparação e seu uso |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |